12:00 AM
 | 
Jan 07, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Cx611: Interim Phase IIa data

Interim data from a placebo-controlled, dose-escalation, Spanish Phase IIa trial in 53 patients with RA showed that all 3 doses of IV Cx611 were safe with...

Read the full 107 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >